Paragonix Technologies Inc., is a privately held medical device company innovating the Sherpa⢠Cardiac Transport System, a novel, single-use organ preservation device to improve donor organ quality and extend donor organ preservation times. The SherpaTM combines innovative oxygenated perfusion of organs and safe organ storage with the goal of extending ischemic time to 12 hours, significantly altering the transportation range of donor hearts. Paragonix Technologies has exclusively licensed intellectual property from the Board of Regents of The University of Texas. Paragonix has established a pipeline of donor organ transport devices that address the current donor organ shortage by maximizing donor organ utilization, improving donor organ quality and extending donor organ transport throughout the entire United States
